Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	Black Diamond Therapeutics	Vaxcyte	Sutro Biopharma	TCR2 Therapeutics	Taysha Gene Therapies
Symbol	NASDAQ:BDTX	NASDAQ:PCVX	NASDAQ:STRO	NASDAQ:TCRR	NASDAQ:TSHA
Price Information
Current Price	$26.56	$19.09	$18.83	$19.01	$20.92
52 Week Range	Buy	Buy	Buy	Buy	Buy
MarketRank™
Overall Score	1.6	1.7	1.3	1.6	1.8
Analysis Score	3.5	3.5	2.5	3.5	3.5
Community Score	2.7	2.9	2.4	2.6	4.0
Dividend Score	0.0	0.0	0.0	0.0	0.0
Ownership Score	1.7	1.7	1.7	1.7	0.8
Earnings & Valuation Score	0.0	0.6	0.0	0.0	0.6
Analyst Ratings
Consensus Recommendation	Buy	Buy	Buy	Buy	Buy
Consensus Price Target	$51.50	$48.00	$24.60	$43.29	$43.92
% Upside from Price Target	93.90% upside	151.44% upside	30.64% upside	127.70% upside	109.93% upside
Trade Information
Market Cap	$960.46 million	$980.37 million	$868.31 million	$724.98 million	$791.13 million
Beta	N/A	N/A	0.8	2.13	N/A
Average Volume	414,149	369,527	509,733	503,175	85,356
Sales & Book Value
Annual Revenue	N/A	N/A	$42.74 million	N/A	N/A
Price / Sales	N/A	N/A	20.32	N/A	N/A
Cashflow	N/A	N/A	N/A	N/A	N/A
Price / Cash	N/A	N/A	N/A	N/A	N/A
Book Value	($1.44) per share	N/A	$4.24 per share	$6.68 per share	N/A
Price / Book	N/A	N/A	4.44	N/A	N/A
Profitability
Net Income	$-35,260,000.00	$-50,270,000.00	$-55,740,000.00	$-47,600,000.00	N/A
EPS	($16.99)	N/A	($2.43)	($4.62)	N/A
Trailing P/E Ratio	N/A	0.00	N/A	N/A	0.00
Forward P/E Ratio	N/A	N/A	N/A	N/A	N/A
P/E Growth	N/A	N/A	N/A	N/A	N/A
Net Margins	N/A	N/A	27.60%	N/A	N/A
Return on Equity (ROE)	-22.28%	N/A	-41.86%	-35.51%	N/A
Return on Assets (ROA)	-17.91%	N/A	-29.50%	-34.02%	N/A
Dividend
Annual Payout	N/A	N/A	N/A	N/A	N/A
Dividend Yield	N/A	N/A	N/A	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	N/A	N/A	0.10%	N/A	N/A
Current Ratio	29.67%	10.12%	9.77%	32.38%	24.02%
Quick Ratio	29.66%	10.12%	9.77%	32.38%	24.02%
Ownership Information
Institutional Ownership Percentage	65.78%	74.08%	78.80%	82.05%	42.19%
Insider Ownership Percentage	N/A	N/A	28.90%	27.99%	N/A
Miscellaneous
Employees	69	58	195	118	38
Shares Outstanding	36.16 million	51.36 million	46.11 million	38.14 million	37.82 million
Next Earnings Date	8/10/2021 (Estimated)	8/11/2021 (Estimated)	8/5/2021 (Estimated)	N/A	8/10/2021 (Estimated)
Optionable	Not Optionable	Not Optionable	Not Optionable	Not Optionable	Not Optionable

Source	Headline
	Taysha Gene Therapies (NASDAQ:TSHA) Sees Large Volume Increase americanbankingnews.com - May 13 at 11:54 AM
	Analysts Issue Forecasts for Taysha Gene Therapies, Inc.'s Q1 2021 Earnings (NASDAQ:TSHA) americanbankingnews.com - May 13 at 8:22 AM
	Taysha Gene Therapies' (TSHA) CEO RA Session II on Q1 2021 Results - Earnings Call Transcript seekingalpha.com - May 12 at 7:11 PM
	Taysha Gene Therapies to Participate in Upcoming May Investor Healthcare Conferences finance.yahoo.com - May 12 at 7:11 PM
	Taysha Gene Therapies (NASDAQ:TSHA) Releases Earnings Results, Misses Expectations By $0.33 EPS americanbankingnews.com - May 12 at 2:38 PM
	Taysha Gene Therapies (NASDAQ:TSHA) Shares Gap Up to $20.52 americanbankingnews.com - May 12 at 10:58 AM
	Taysha Gene Therapies Reports First Quarter 2021 Financial Results and Provides a Corporate Update finance.yahoo.com - May 11 at 9:45 AM
	Taysha Gene Therapies' Rett Syndrome Candidate Shows Encouraging Action In Animal Studies, Human Trial To Start By 2021 finance.yahoo.com - May 10 at 7:24 PM
	Taysha Gene Therapies Announces Publication of Preclinical Data for TSHA-102 in Rett Syndrome in Brain, a Highly Esteemed Neurological Science Peer-Re us.acrofan.com - May 10 at 9:23 AM
	Taysha Gene Therapies Announces Publication of Preclinical Data for TSHA-102 in Rett Syndrome in Brain, a Highly Esteemed Neurological Science Peer-Reviewed Journal finance.yahoo.com - May 10 at 9:23 AM
	Reviewing Taysha Gene Therapies (NASDAQ:TSHA) & Vir Biotechnology (NASDAQ:VIR) americanbankingnews.com - May 7 at 1:38 AM
	Taysha Gene Therapies (NASDAQ:TSHA) Trading Up 7.3% americanbankingnews.com - May 6 at 2:52 PM
	Taysha Gene Therapies (NASDAQ:TSHA) Shares Gap Down to $22.68 americanbankingnews.com - May 5 at 1:15 PM
	Taysha Gene Therapies (TSHA) to Release Quarterly Earnings on Tuesday americanbankingnews.com - May 5 at 11:13 AM
	Taysha Gene Therapies Announces Multiple Data Presentations and Workshop Presentations at the 24th Annual Meeting of the American Society of Gene & Ce us.acrofan.com - May 5 at 8:26 AM
	Taysha Gene Therapies Announces Multiple Data Presentations and Workshop Presentations at the 24th Annual Meeting of the American Society of Gene & Cell Therapy finance.yahoo.com - May 5 at 8:26 AM
	Taysha Gene Therapies (NASDAQ:TSHA) Sees Strong Trading Volume americanbankingnews.com - May 4 at 12:48 PM
	Taysha Gene Therapies to Release First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 11 finance.yahoo.com - May 4 at 9:57 AM
	-$0.54 EPS Expected for Taysha Gene Therapies, Inc. (NASDAQ:TSHA) This Quarter americanbankingnews.com - May 3 at 6:46 PM
	Taysha Gene Therapies (NASDAQ:TSHA) Trading Down 6.8% americanbankingnews.com - May 3 at 2:28 PM
	Taysha Gene Therapies Inc (TSHA) investing.com - April 29 at 5:50 PM
	Taysha Gene Therapies (NASDAQ:TSHA) Receives Buy Rating from Chardan Capital americanbankingnews.com - April 29 at 10:04 AM
	Taysha Gene Therapies (NASDAQ:TSHA) Shares Up 6.5% americanbankingnews.com - April 27 at 11:38 AM
	Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Consensus Recommendation of "Buy" from Analysts americanbankingnews.com - April 23 at 6:50 AM
	Taysha Gene Therapies (NASDAQ:TSHA) Trading Down 5.3% americanbankingnews.com - April 22 at 2:46 PM

Date	Company	Brokerage	Action
3/26/2021	Black Diamond Therapeutics	HC Wainwright	Reiterated Rating
1/19/2021	Black Diamond Therapeutics	Canaccord Genuity	Reiterated Rating
1/6/2021	Black Diamond Therapeutics	Wedbush	Initiated Coverage
11/24/2020	Black Diamond Therapeutics	Berenberg Bank	Initiated Coverage
2/24/2020	Black Diamond Therapeutics	Cowen	Initiated Coverage
2/24/2020	Black Diamond Therapeutics	Jefferies Financial Group	Initiated Coverage
2/24/2020	Black Diamond Therapeutics	JPMorgan Chase & Co.	Initiated Coverage
8/14/2020	Vaxcyte	Needham & Company LLC	Reiterated Rating
7/7/2020	Vaxcyte	Bank of America	Initiated Coverage
7/7/2020	Vaxcyte	Cantor Fitzgerald	Initiated Coverage
1/28/2021	Sutro Biopharma	Truist	Boost Price Target
12/2/2020	Sutro Biopharma	Stifel Nicolaus	Initiated Coverage
11/6/2020	Sutro Biopharma	Piper Sandler	Boost Price Target
7/16/2020	Sutro Biopharma	Wells Fargo & Company	Initiated Coverage
5/12/2020	Sutro Biopharma	B. Riley	Downgrade
1/13/2020	Sutro Biopharma	SunTrust Banks	Initiated Coverage
10/7/2019	Sutro Biopharma	BTIG Research	Initiated Coverage
9/5/2019	Sutro Biopharma	JMP Securities	Reiterated Rating
7/18/2019	Sutro Biopharma	Deutsche Bank Aktiengesellschaft	Initiated Coverage
5/13/2021	TCR2 Therapeutics	Mizuho	Initiated Coverage
3/17/2021	TCR2 Therapeutics	SVB Leerink	Lower Price Target
3/11/2021	TCR2 Therapeutics	BMO Capital Markets	Lower Price Target
11/30/2020	TCR2 Therapeutics	Roth Capital	Boost Price Target
8/12/2020	TCR2 Therapeutics	Truist Financial	Initiated Coverage
4/26/2021	Taysha Gene Therapies	Chardan Capital	Reiterated Rating
4/19/2021	Taysha Gene Therapies	Morgan Stanley	Boost Price Target
3/1/2021	Taysha Gene Therapies	William Blair	Initiated Coverage
1/4/2021	Taysha Gene Therapies	Oppenheimer	Initiated Coverage
10/19/2020	Taysha Gene Therapies	The Goldman Sachs Group	Initiated Coverage

(Data available from 5/14/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Comparison Ideas:

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources